MX6A Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Grand Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.51 |
| 52 Week High | HK$0.62 |
| 52 Week Low | HK$0.38 |
| Beta | 0.73 |
| 11 Month Change | -13.68% |
| 3 Month Change | 8.37% |
| 1 Year Change | -3.81% |
| 33 Year Change | -27.86% |
| 5 Year Change | n/a |
| Change since IPO | -28.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| MX6A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.3% | -1.0% | 0.2% |
| 1Y | -3.8% | -19.3% | 8.5% |
Return vs Industry: MX6A exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: MX6A underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| MX6A volatility | |
|---|---|
| MX6A Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: MX6A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MX6A's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 10,775 | Chao Zhou | www.grandpharm.com |
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products.
Grand Pharmaceutical Group Limited Fundamentals Summary
| MX6A fundamental statistics | |
|---|---|
| Market cap | €1.87b |
| Earnings (TTM) | €297.13m |
| Revenue (TTM) | €1.31b |
6.3x
P/E Ratio1.4x
P/S RatioIs MX6A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MX6A income statement (TTM) | |
|---|---|
| Revenue | HK$10.59b |
| Cost of Revenue | HK$4.34b |
| Gross Profit | HK$6.25b |
| Other Expenses | HK$3.84b |
| Earnings | HK$2.41b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 59.00% |
| Net Profit Margin | 22.75% |
| Debt/Equity Ratio | 28.1% |
How did MX6A perform over the long term?
See historical performance and comparison